Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 23260347)

1.

Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5.

Olsson RI, Jacobson I, Boström J, Fex T, Björe A, Olsson C, Sundell J, Gran U, Öhrn A, Nordin A, Gyll J, Thorstensson M, Hayen A, Aplander K, Hidestål O, Jiang F, Linhardt G, Forsström E, Collins T, Sundqvist M, Lindhardt E, Åstrand A, Löfberg B.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):706-10. doi: 10.1016/j.bmcl.2012.11.098. Epub 2012 Dec 3.

PMID:
23260347
2.

Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.

Lloyd J, Finlay HJ, Vacarro W, Hyunh T, Kover A, Bhandaru R, Yan L, Atwal K, Conder ML, Jenkins-West T, Shi H, Huang C, Li D, Sun H, Levesque P.

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1436-9. doi: 10.1016/j.bmcl.2009.12.085. Epub 2010 Jan 4.

PMID:
20097068
3.

Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.

Gross MF, Beaudoin S, McNaughton-Smith G, Amato GS, Castle NA, Huang C, Zou A, Yu W.

Bioorg Med Chem Lett. 2007 May 15;17(10):2849-53. Epub 2007 Feb 27.

PMID:
17350840
4.

Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.

Peukert S, Brendel J, Pirard B, Strübing C, Kleemann HW, Böhme T, Hemmerle H.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2823-7.

PMID:
15125940
5.

High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.

Karczewski J, Kiss L, Kane SA, Koblan KS, Lynch RJ, Spencer RH.

Biochem Pharmacol. 2009 Jan 15;77(2):177-85. doi: 10.1016/j.bcp.2008.09.035. Epub 2008 Oct 8.

PMID:
18955031
6.

Novel peptidyl phosphorus derivatives as inhibitors of human calpain I.

Tao M, Bihovsky R, Wells GJ, Mallamo JP.

J Med Chem. 1998 Sep 24;41(20):3912-6.

PMID:
9748367
7.

Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.

Olsson RI, Jacobson I, Iliefski T, Boström J, Davidsson Ö, Fjellström O, Björe A, Olsson C, Sundell J, Gran U, Gyll J, Malmberg J, Hidestål O, Emtenäs H, Svensson T, Yuan ZQ, Strandlund G, Åstrand A, Lindhardt E, Linhardt G, Forsström E, Högberg Å, Persson F, Andersson B, Rönnborg A, Löfberg B.

Bioorg Med Chem Lett. 2014 Mar 1;24(5):1269-73. doi: 10.1016/j.bmcl.2014.01.067. Epub 2014 Jan 30.

PMID:
24513046
8.

Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.

Lagrutta A, Wang J, Fermini B, Salata JJ.

J Pharmacol Exp Ther. 2006 Jun;317(3):1054-63. Epub 2006 Mar 7.

9.

Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode.

Strutz-Seebohm N, Gutcher I, Decher N, Steinmeyer K, Lang F, Seebohm G.

Cell Physiol Biochem. 2007;20(6):791-800.

PMID:
17982261
11.

Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.

Gross MF, Castle NA, Zou A, Wickenden AD, Yu W, Spear KL.

Bioorg Med Chem Lett. 2009 Jun 1;19(11):3063-6. doi: 10.1016/j.bmcl.2009.04.002. Epub 2009 Apr 8.

PMID:
19398199
12.

Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.

Johnson JA, Xu N, Jeon Y, Finlay HJ, Kover A, Conder ML, Sun H, Li D, Levesque P, Hsueh MM, Harper TW, Wexler RR, Lloyd J.

Bioorg Med Chem Lett. 2014 Jul 15;24(14):3018-22. doi: 10.1016/j.bmcl.2014.05.035. Epub 2014 May 20.

PMID:
24881565
13.

Synthesis and glycogen phosphorylase inhibitory activity of N-(beta-D-glucopyranosyl)amides possessing 1,4-benzodioxane moiety.

Czakó Z, Juhász L, Kenéz A, Czifrák K, Somsák L, Docsa T, Gergely P, Antus S.

Bioorg Med Chem. 2009 Sep 15;17(18):6738-41. doi: 10.1016/j.bmc.2009.07.052. Epub 2009 Jul 25.

PMID:
19703777
14.

Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.

Peukert S, Brendel J, Pirard B, Brüggemann A, Below P, Kleemann HW, Hemmerle H, Schmidt W.

J Med Chem. 2003 Feb 13;46(4):486-98.

PMID:
12570371
15.

Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors.

Guo X, Yang Q, Xu J, Zhang L, Chu H, Yu P, Zhu Y, Wei J, Chen W, Zhang Y, Zhang X, Sun H, Tang Y, You Q.

Bioorg Med Chem. 2013 Nov 1;21(21):6466-76. doi: 10.1016/j.bmc.2013.08.041. Epub 2013 Aug 31.

PMID:
24071446
16.
17.

In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.

Regan CP, Wallace AA, Cresswell HK, Atkins CL, Lynch JJ Jr.

J Pharmacol Exp Ther. 2006 Feb;316(2):727-32. Epub 2005 Oct 21.

18.

Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).

Yang MG, Xiao Z, Shi Q, Cherney RJ, Tebben AJ, De Lucca GV, Santella JB 3rd, Mo R, Cvijic ME, Zhao Q, Barrish JC, Carter PH.

Bioorg Med Chem Lett. 2012 Feb 1;22(3):1384-7. doi: 10.1016/j.bmcl.2011.12.057. Epub 2011 Dec 16.

PMID:
22225639
19.

Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).

Guo X, Ma X, Yang Q, Xu J, Huang L, Jia J, Shan J, Liu L, Chen W, Chu H, Wei J, Zhang X, Sun H, Tang Y, You Q.

Eur J Med Chem. 2014 Jun 23;81:89-94. doi: 10.1016/j.ejmech.2014.03.075. Epub 2014 Mar 28.

PMID:
24824064
20.

Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers.

Wu S, Fluxe A, Janusz JM, Sheffer JB, Browning G, Blass B, Cobum K, Hedges R, Murawsky M, Fang B, Fadayel GM, Hare M, Djandjighian L.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5859-63. Epub 2006 Aug 30.

PMID:
16942874
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk